Where the Concern Started

Early rodent studies showed C-cell thyroid tumors in rats given extremely high doses of GLP-1 drugs.

That led to the FDA’s required warning label—but humans and rodents have very different C-cell receptor densities.

To date, no increase in medullary thyroid carcinoma (MTC) has been demonstrated in human trials.

What the Human Data Show

• Across large studies (STEP 1–5, SURMOUNT 1–2, SUSTAIN 1–10), zero confirmed MTC cases were reported.
  

• GLP-1 receptors in human thyroid tissue are scarce.
  

• The medications have not been shown to raise TSH or cause hypothyroidism in euthyroid patients.
  
  

The warning remains purely precautionary, especially for people with a personal or family history of MTC or MEN-2.

If You Have Thyroid Disease

Most thyroid disorders—Hashimoto’s, hypothyroidism, or simple nodules—are not contraindications.

If your thyroid levels are stable, GLP-1s are considered safe.
 Monitoring TSH every 6–12 months is standard practice.

The Bottom Line

GLP-1s are among the most well-studied metabolic medications in history.
For the general population, the benefits far outweigh the theoretical thyroid risk.

If you have a strong family history of thyroid cancer or MEN-2, discuss alternative therapies—but for everyone else, GLP-1s remain a safe and powerful option.

Start Confidently

Join a medically supervised GLP-1 program with Dr Sara and get clear, evidence-based guidance on your thyroid and metabolism. Learn more at drbrainrx.com.

References

1. Marso SP et al. NEJM. 2016;375:311–322.
   

2. Jastreboff AM et al. NEJM. 2022;387:205–216.
   

3. FDA Drug Safety Communication, 2023.